Acute respiratory distress syndrome. Potential pharmacologic interventions

Related Experiment Video

Updated: Aug 12, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

B D Conner1, G R Bernard

  • 1Center for Lung Research, Vanderbilt University, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Clinics in Chest Medicine
|October 6, 2000
PubMed

Insights

Significant progress in understanding acute lung injury mediators has been made. While new therapies for ARDS are still pending, research has improved, setting the stage for future clinical testing.

Area of Science:

  • Physiology
  • Immunology
  • Critical Care Medicine

Background:

  • Acute lung injury (ALI) involves complex interactions of numerous potent physiologic mediators.
  • Sepsis is the primary cause of ALI, necessitating research into both conditions.
  • Understanding ALI pathogenesis has been challenging due to mediator complexity.

Purpose of the Study:

  • To review the progress in understanding the interplay of mediators in acute lung injury over the past decade.
  • To highlight the advancements in clinical studies related to ALI and sepsis.
  • To establish the current status and future directions for ALI research and therapy development.

Main Methods:

  • Review of recent clinical studies focusing on acute lung injury (ALI) and sepsis.
  • Analysis of the progress in understanding the role of physiologic mediators in ALI.
  • Assessment of the quality and scale of clinical research in the field.

Main Results:

  • Despite complex interactions, significant progress has been made in understanding ALI mediators.
  • Clinical studies in ALI and sepsis have increased in number, size, and quality.
  • No accepted new therapies for ALI have emerged, but foundational work is complete.

Conclusions:

  • The groundwork for future advancements in ALI treatment has been established.
  • The current research landscape is prepared for rigorous and efficient clinical testing of new therapeutic strategies.
  • Further investigation into mediator interplay is crucial for developing effective ALI therapies.

More Related Videos

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)

Published on: April 7, 2021

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...